New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents

BayerWith approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. "We need dedicated and creative young scientists if we are to successfully shape the future. That's why with the Bayer Fellowship Program we are helping talented young people to participate in special projects abroad," says Kemal Malik, Bayer Management Board member responsible for Innovation.

Today's "Bayer Fellowship program" follows the tradition of the first company scholarships initiated back in 1923 by Dr. Carl Duisberg, at that time Managing Director of the Bayer Group. Duisberg is regarded as a pioneer in the intensive cooperation between industry and universities, as well as in corporate social responsibility. Explains Dr. Carl-Heinz Duisberg, member of the Scientific Committee of the Bayer Fellowship Program and youngest grandchild of the program's founder: "My grandfather wanted to provide the best development opportunities for young talents because he saw this as a means of ensuring long-term benefits for society. He is also quoted as saying 'We must spend every spare penny on science - it is the best investment we can make.'"

All scholarships underline the mission of the Bayer foundation to work with young people and the next generation of scientists and opinion-leaders and to strengthen interest in the major challenges facing our society, such as health and agriculture.

Alongside the Otto Bayer, Jozef Schell and Carl Duisberg scholarships, the Bayer Fellowship Program also includes the Kurt Hansen and Hermann Strenger scholarships. For the third time, the Bayer Science & Education Foundation offers an additional special budget for "Talents for Africa". The scholarships are targeted at students and vocational trainees in natural science and medical disciplines who would like to realize a particular foreign study project and require financial support for this. In addition to Germany-based applicants who would like to study abroad, the foundation supports scholarship recipients from outside of Germany who wish to realize a comparable project in Germany.

Academic disciplines receiving support this year include the life sciences, chemistry, agriculture as well as human and veterinary medicine, with a total of 56 scholarships being awarded. Three Kurt Hansen scholarship recipients are also receiving assistance for teacher training in the natural sciences. The scholarships in the academic sector are being supplemented by Hermann Strenger scholarships to support young people looking to gain initial work experience abroad as part of a non-academic training program. This year, six young people from Germany are being supported who are planning a period abroad as part of their commercial, technical or health profession training.

Thanks to the Bayer scholarships, 47 new fellows from Germany will start their projects in 18 different countries: Argentina, Australia, Brazil, Chile, Ethiopia, France, Gabon, Israel, Mexico, Nicaragua, Russian Federation, Rwanda, Spain, Sri Lanka, Sweden, Switzerland, United Kingdom and the United States. Another 18 new scholarship winners will be able to implement their individual projects in Germany, coming from: Austria, Bangladesh, Brazil, Canada, Egypt, Finland, Italy, Mexico, Morocco, Netherlands, Nigeria, Pakistan, Russian Federation, Singapore, Syria, Tunisia, Turkey and United Kingdom.

The Bayer Science & Education Foundation thus is launching the eleventh round of its funding program, which offers targeted support for scientific exchange and international work experience for young people. It targets creative, highly motivated and socially committed young people with above-average grades.

The next round of applications starts in June 2018.

More information is available on the Internet at www.bayer-foundations.com.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...